Quidel Stock News

Quidel's revenue will grow at a CAGR of high-single-digits in the next five years. The company's Sofia, Sofia 2, and Triage MeterPro products will drive revenue growth.

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fi

Quidel recorded its best-ever revenue performance in 2021 at $1.699 billion despite its gross profit falling to $1.271 billion YOY.

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

WASHINGTON, March 11, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Heart Failure POC & LOC Devices Market finds that factors such as, increasing geriatric population base, growing research & development activities and rising cardiovascular diseases are augmenting the growth of Heart Failure POC & LOC Devices Market in upcoming time span. The total Global Heart Failure POC & LOC Devices Market is estimated to reach USD 180.1 Million by 2028. The Market stood at a revenue of USD 55.9 Million in the year 2021, and is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 16.5%, states Vantage Market Research, in a report, titled " Heart Failure POC & LOC Devices Market by Test Type (Proteomic Testing, Metabolomic Testing, Genomic Testing), by Technology (Microfluidics, Array-based Systems, Others), by End Use (Clinics, Hospitals, Home, Assisted Living Healthcare Facilities), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James & Associates 43rd Annual Institutional Investors Conference to be held at the J.W. Marriott Orlando Grande Lakes hotel in Orlando, Florida on Wednesday, March 9, 2022 at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time). Douglas Bryant, president and c

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced toda

A significant analyst upgrade keeps the stock''s bull run going.

A significant analyst upgrade keeps the stock's bull run going.

The COVID-19 test maker Quidel (QDEL) is trading higher on Tuesday morning hours after Raymond James upgraded the stock to Strong Buy from Outperform. Read more.

After back-to-back sessions of losses, Quidel <> closed higher on Friday as Wall Street reacted to the COVID-19 test maker’s strong revenue beat for Q4 2021

US stocks remained lower toward the end of trading, with the Nasdaq dropping 150 points on Friday. The Dow traded down 0.39% to 34,178.62 while the NASDAQ fell 1.1% to 13,567. The S&P also fell, dropping, 0.55% to 4,356.37. Check this out: Boeing And 3 Other Stocks Bought By Insiders Leading and Lagging Sectors Consumer staples shares slipped by just 0.3% on Friday. Meanwhile, top gainers in the sector included Local Bounti Corporation (NYSE: LOCL ), up 3% and Landec Corporation (NASDAQ: LNDC ) up 2%. In trading on Friday, information technology shares tumbled by 1.4%. Top Headline Deere & Company (NYSE: DE ) reported better-than-expected results for its first quarter and raised profit guidance. Deere posted quarterly earnings of $2.92 per share, beating market estimates of $2.26 per share. The company’s quarterly sales came in at $9.57 billion, versus expectations of $8.19 billion. Deere boosted its FY22 net income guidance from $6.5 billion-$7 billion to $6.7 billion-$7.1 billion. Equities Trading UP T2 Biosystems, Inc. (NASDAQ: TTOO ) shares shot up 14% to $0.4579 after the company reported better-than-expected Q4 EPS and sales results.

The company handily beat Wall Street earnings expectations.

Despite robust revenues from COVID-19 products, Quidel (QDEL) records an overall soft Q4 performance.